Hepatocellular carcinoma

By J. Llovet, J. Zucman‐Rossi, E. Pikarsky, B. Sangro, M. Schwartz, M. Sherman, G. Gores. Nature Reviews Disease Primers, 2016

1,645 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/7bfd74fd43ae05ebf508d30488f8928933722ec2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Natascha Roehlen
2. E. Crouchet
3. T. Baumert

In Hepatology

1. Natascha Roehlen
2. E. Crouchet
3. T. Baumert

Citations in the corpus

• Advances in immunotherapy for hepatocellular carcinoma (2021, neutral): “Nivolumab (240 mg every 2 weeks) Cabozantinib (40 mg every day) Mix 36 39 47 39 14 (3) 19 21.”
• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “Thus, the level of fibrosis correlates with liver function and represents the major risk factor for development of hepatocellular carcinoma (HCC) [4].”
• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, neutral): “Black/African American 2 (2) Other 5 (5) Missing 14 (14)”